Skip to content
Snippets Groups Projects
Commit 8f5888fe authored by Christian Roever's avatar Christian Roever
Browse files

extended 'Peto1980' data set

parent 2a7b4224
No related branches found
No related tags found
No related merge requests found
Hide whitespace changes
Inline Side-by-side
DESCRIPTION
+ 1
− 1
View file @ 8f5888fe
......@@ -2,7 +2,7 @@ Package: bayesmeta
Type: Package
Title: Bayesian Random-Effects Meta-Analysis and Meta-Regression
Version: 3.3
Date: 2023-01-12
Date: 2023-03-16
Authors@R: c(person(given="Christian", family="Roever", role=c("aut","cre"),
email="christian.roever@med.uni-goettingen.de",
comment=c(ORCID="0000-0002-6911-698X")),
......
data/Peto1980.R
+ 15
− 7
View file @ 8f5888fe
#
# S.E. Brockwell, I.R. Gordon. A comparison of statistical methods for meta-analysis.
# Statistics in Medicine, 20(6):825-840, 2001.
#
# R. Peto. Aspirin after myocardial infarction.
# The Lancet 315(8179):1172-1173, 1980.
# https://doi.org/10.1016/S0140-6736(80)91626-8
#
# P.L. Canner. An overview of six clinical trials of aspirin in coronary heart disease.
# Statistics in Medicine, 6(3):255-263, 1987.
# https://doi.org/10.1002/sim.4780060310
#
Peto1980 <- cbind.data.frame("publication" =c("BrMedJ1974","JChronDis1976","Haemostasis1980",
"Lancet1979","JAMA1980","Circulation1980"),
"treat.cases" =c(615, 758, 317, 832, 810, 2267),
"treat.events" =c(49, 44, 27, 102, 85, 246),
"control.cases" =c(624, 771, 309, 850, 406, 2257),
"control.events"=c(67, 64, 32, 126, 52, 219),
"study" =c("UK-1","CDPA","GAMS","UK-2","PARIS","AMIS"),
"start" =as.integer(c(1971, 1972, 1970, 1975, 1975, 1975)),
"end" =as.integer(c(1973, 1975, 1977, 1979, 1979, 1979)),
"age" =c(55.0, 56.5, 58.9, 56.2, 56.3, 54.8),
"dose" =c(300, 972, 1500, 900, 972, 1000),
"followup" =c(11.9, 22.0, 24.0, 12.0, 41.0, 39.6),
"treat.cases" =as.integer(c(615, 758, 317, 832, 810, 2267)),
"treat.events" =as.integer(c(49, 44, 27, 102, 85, 246)),
"control.cases" =as.integer(c(624, 771, 309, 850, 406, 2257)),
"control.events"=as.integer(c(67, 64, 32, 126, 52, 219)),
stringsAsFactors=FALSE)
man/KarnerEtAl2014.Rd
+ 4
− 3
View file @ 8f5888fe
......@@ -12,7 +12,7 @@
\bold{inhaler} \tab \code{factor} \tab type of inhaler investigated (\dQuote{dry powder} or \dQuote{soft mist}) \cr
\bold{baseline.age} \tab \code{numeric} \tab mean age at baseline \cr
\bold{baseline.males} \tab \code{numeric} \tab proportion of males among study participants \cr
\bold{baseline.fev1} \tab \code{numeric} \tab mean FEV1 at baseline \cr
\bold{baseline.fev1} \tab \code{numeric} \tab mean FEV1 at baseline (L) \cr
\bold{baseline.fev1pp} \tab \code{numeric} \tab mean FEV1 (percent of predicted) at baseline \cr
\bold{baseline.pyr} \tab \code{numeric} \tab mean number of pack-years (smoking history) \cr
\bold{tiotropium.total} \tab \code{numeric} \tab total number of patients in the treatment group \cr
......@@ -30,7 +30,7 @@
\bold{placebo.sae} \tab \code{numeric} \tab number of patients with \eqn{\geq 1}{>=1} serious adverse event (non-fatal) in the control group \cr
\bold{placebo.dropout} \tab \code{numeric} \tab number of withdrawals in the control group \cr
\bold{sgrq.md}, \bold{sgrq.se} \tab \code{numeric} \tab mean difference and associated standard error for \emph{St. George's respiratory questionnaire (SGRQ)} total score \cr
\bold{fev1.md}, \bold{fev1.se} \tab \code{numeric} \tab mean difference and associated standard error for \emph{forced expiratory volume in 1 second (FEV1)} \cr
\bold{fev1.md}, \bold{fev1.se} \tab \code{numeric} \tab mean difference and associated standard error for \emph{forced expiratory volume in 1 second (FEV1, mL)} \cr
}
}
\details{Chronic obstructive pulmonary disease (COPD) is a chronic and
......@@ -38,7 +38,8 @@
phases. Various treatment options are available, aimed at both
providing relief during an acute exacerbation, and at delaying overall
disease progression. A common drug used in the management of COPD is
\emph{tiotropium}, which is administered via an inhaler device.
\emph{tiotropium}, a long-acting muscarinic antagonist (LAMA), which
is administered via an inhaler device.
Karner \emph{et al.} (2014) conducted a systematic review in order to
evaluate the evidence on the effects of tiotropium in comparison to
......
man/Peto1980.Rd
+ 27
− 14
View file @ 8f5888fe
......@@ -7,24 +7,37 @@
\usage{data("Peto1980")}
\format{The data frame contains the following columns:
\tabular{lll}{
\bold{publication} \tab \code{character} \tab publication identifier \cr
\bold{treat.cases} \tab \code{numeric} \tab number of cases in treatment group \cr
\bold{treat.events} \tab \code{numeric} \tab number of events in treatment group \cr
\bold{control.cases} \tab \code{numeric} \tab number of cases in control group \cr
\bold{control.events} \tab \code{numeric} \tab number of events in control group \cr
\bold{publication} \tab \code{character} \tab publication reference \cr
\bold{study} \tab \code{character} \tab study acronym or abbreviation \cr
\bold{start}, \bold{end} \tab \code{integer} \tab duration of study (calendar years) \cr
\bold{age} \tab \code{numeric} \tab mean patient age (years) \cr
\bold{dose} \tab \code{numeric} \tab total daily dose (mg) \cr
\bold{followup} \tab \code{numeric} \tab follow-up duration (months) \cr
\bold{treat.cases} \tab \code{integer} \tab number of cases in treatment group \cr
\bold{treat.events} \tab \code{integer} \tab number of events in treatment group \cr
\bold{control.cases} \tab \code{integer} \tab number of cases in control group \cr
\bold{control.events} \tab \code{integer} \tab number of events in control group \cr
}
}
\details{
Quoting from Brockwell and Gordon (2001):
\dQuote{The collection consists of six studies, each examining the
effect of aspirin after myocardial infarction. In each study the
number of patients who died after having been given either aspirin
or a control drug is recorded.}
Peto (1980) investigated mortality data from six randomized,
placebo-controlled clinical trials of aspirin, involving a total of
10,703 post-myocardial infarction patients. Canner (1987) later investigated
potential heterogeneity between study characteristics as well as their
reported estimates. The included studies' abbreviations are:
\tabular{ll}{
UK-1 \tab first United Kingdom trial \cr
CDPA \tab Coronary Drug Project Aspirin trial \cr
GAMS \tab German-Austrian Multicentre Study\cr
UK-2 \tab second United Kingdom trial \cr
PARIS \tab Persantine-Aspirin Reinfarction Study \cr
AMIS \tab Aspirin Myocardial Infarction Study
}
}
\source{S.E. Brockwell, I.R. Gordon.
A comparison of statistical methods for meta-analysis.
\emph{Statistics in Medicine}, \bold{20}(6):825-840, 2001.
\doi{10.1002/sim.650}.
\source{P.L. Canner. An overview of six clinical trials of aspirin
in coronary heart disease.
\emph{Statistics in Medicine}, \bold{6}(3):255-263, 1987.
\doi{10.1002/sim.4780060310}
}
\references{R. Peto.
Aspirin after myocardial infarction.
......
man/bayesmeta-package.Rd
+ 1
− 1
View file @ 8f5888fe
......@@ -16,7 +16,7 @@
Package: \tab bayesmeta\cr
Type: \tab Package\cr
Version: \tab 3.3\cr
Date: \tab 2022-01-12\cr
Date: \tab 2023-03-16\cr
License: \tab GPL (>=2)
}
The main functionality is provided by the \code{\link{bayesmeta}()}
......
0% or .
You are about to add 0 people to the discussion. Proceed with caution.
Finish editing this message first!
Please register or to comment